Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970–1979 1974: FDA approves doxorubicin.

Slides:

Advertisements

Similar presentations

Major Cancer Milestones

Advertisements

Progress Against Breast Cancer

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Progress Against Lung Cancer. 1970–1979 Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung.

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.

Progress Against Bladder Cancer. Pre-1970 Progress Against Bladder Cancer Pre : Tool offers view inside bladder for first time.

Progress Against Ovarian Cancer. 1970–1979 Progress Against Ovarian Cancer 1970– : First effective combination chemotherapy regimen for ovarian.

Progress Against Testicular Cancer. 1970–1979 Progress Against Testicular Cancer 1970– : Two new drugs produce first complete remissions in advanced.

Progress Against Cervical Cancer. 1980–1989 Progress Against Cervical Cancer 1980– –1984: HPV virus is discovered to cause cervical cancer.

Progress Against Head and Neck Cancer. 1970–1979.

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Progress Against Kidney Cancer. 1970–1979 Progress Against Kidney Cancer 1970– : Removing just part of the cancerous kidney is proven safe and.

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Progress Against Liver Cancer. 1970–1979 Progress Against Liver Cancer 1970– : First study finds chemotherapy effective for liver cancer.

Presenter Name(s) Issue date National Student.

First cases of AIDS identified.

Through the years… JUNIATA COLLEGE FIELD HOCKEY. SeasonCoachRecord 1973Unknown Jo Reilly Alexa Fultz Alexa Fultz Nancy Harden-Latimore4-4-1.

From Delft into Almere Prof.dr.ir.Taeke M. de Jong.

Reduced Incidence of ESRD among 60 to 80–year-olds in Denmark Heaf JG 1, Wehberg S 2, Engberg H 2 Danish Nephrology Registry 1 Herlev Hospital, University.

Name ____________________ Date ___________ Period ____.

Trends in incidence and mortality, England 1989 to 2010.

Wednesday, February 15th Seth Wander

My Bone Marrow… My Blood… My Life… By Alpha-Bots December 2010.

Chronic leukaemias Chronic myelogenous leukaemia Chronic myelogenous leukaemia Chronic lymphocytic leukaemia Chronic lymphocytic leukaemia.

What is Leukemia? Leukemia is cancer of the blood. Often times, symptoms of Leukemia go unnoticed or do not appear at all in the early stages. Because.

Leukemia By Mary Chen and Genesis Pimentel

This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.

Educational Presentation. Program Overview Provide information on The Leukemia & Lymphoma Society Describe blood cancers Explain Pennies for Patients.

Anticancer Therapy: Kinase Inhibitors Charles Harrell.

LEUKEMIA. What Is It? Leukemia is a type of cancer that starts in the tissue that forms blood.

By Taylor, Lanny, and Alex. What is it?  Leukemia is an abnormal rise in the number of white blood cells. The white blood cells crowd out other blood.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Marty O’Neill II Carmen Banea

 “Resident Expert Presentation” Leukemia Khadija Andrews CEP 661 Medical Psychology.

My Bone Marrow… My Blood… My Life… By Alpha-Bots December 2010.

Pluripotent hematopoietic stem cells are common ancestral cells for all blood and immune cells.

Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.

Chronic Non-Infectious: Cancer

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Sami Sasala Brooke McVay Tiffany Vandiver

Treatment of Leukemias and Lymphomas December 2013.

Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

Blood Cancers in older adults Cancer and Older Adults 19 November 2015 Matthew Foster, MD Assistant Professor of Medicine Leukemia, Lymphoma and Myeloma.

ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.

Hematopoetic Cancers. Hematopoesis Leukemia New diagnoses each year in the US: 40, 800 Adults 3,500 Children 21,840 died of leukemia in 2010.

By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.

Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.

ONCOGENE AND ITS ROLE IN THE DEVELOPMENT OF LEUKAEMIA Nouf khaled al-Hajjar SUPERVISOR Dr.SAMINA HAQ.

Leukemia By: Manuel Gomez. What is leukemia  Leukemia also called blood cancer  A disease in which the bone marrow and organs that form blood, produce.

Wraparound Fundraising May LLS is focused on cures While other large cancer organizations target their mission investment on prevention and early.

Evolving Therapies for Elderly Patients with Blood Cancers

CHRONIC MYELOID LEUKEMIA (CML)

ENVL-GEOL, SUST and CHEM

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Mak Shu Ting (18) Yip Pui Yue (29)

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

CLL - When to treat, how to treat

Neoplastic disorder.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Leukemia By: Fabiola Dominguez.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova

The Pathway to Progress Against Chronic Myelogenous Leukemia.

Presentation transcript:

Progress Against Leukemia

1970–1979

Progress Against Leukemia 1970– : FDA approves doxorubicin

Progress Against Leukemia 1970– : Era of bone marrow transplantation begins – extending lives of many patients with leukemia and lymphoma

Progress Against Leukemia 1970– : Chlorambucil induces remissions for chronic lymphocytic leukemia

Progress Against Leukemia 1980–1989

Progress Against Leukemia 1980– : Daunorubicin proven superior to doxorubicin for AML

Progress Against Leukemia 1980– : National bone marrow transplantation registry is established

Progress Against Leukemia 1980–1989 Late 1980s: Benzene established to cause cancer

Progress Against Leukemia 1990–1999

Progress Against Leukemia 1990– : Lymphocyte transfusions re-induce leukemia remissions 1995: Approval of tretinoin leads to 95 percent cure rate for rare leukemia

Progress Against Leukemia 2000–Present

Progress Against Leukemia 2000–Present 2000: Fludarabine works faster, better for patients with CLL

Progress Against Leukemia 2000–Present 2001: New targeted therapy – imatinib – proven effective against chronic myelogenous leukemia

Progress Against Leukemia 2000–Present 2004, 2006: Epigenetic drugs approved to prevent cancer in patients with myelodysplastic syndromes

Progress Against Leukemia 2000–Present 2005: Drug approved to reduce oral sores caused by cancer treatment

Progress Against Leukemia 2000–Present 2006: New drug helps CML patients who become resistant to imatinib

Progress Against Leukemia 2000–Present 2007: Addition of an arsenic compound found to improve survival for rare form of leukemia 2007: Study supports expanded use of dasatinib for CML 2007: Bendamustine is effective against chronic lymphocytic leukemia (CLL)

Progress Against Leukemia 2000–Present 2009: Genome of acute myelogenous leukemia is sequenced

Progress Against Leukemia 2000–Present 2010: Tyrosine kinase inhibitors provide additional options for CML 2011: Adding rituximab extends survival for chronic lymphocytic leukemia

Progress Against Leukemia Five-Year Survival Source: National Cancer Institute

Progress Against Leukemia Mortality Source: National Cancer Institute

Progress Against Leukemia New Cases Source: National Cancer Institute

Visit CancerProgress.Net for an interactive timeline of progress against a range of common cancers CancerProgress.Net is a project of the American Society of Clinical Oncology, which represents nearly 30,000 physicians who treat people with cancer and research new cures